Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mauro Schechter

Showing results (41-50 of 118) with videos related to

Pageof 12
Sort By:
AIDS (London, England)|December 5, 2013
Interleukin-6 and D-dimer levels at seroconversion as predictors of HIV-1 disease progressionElizabeth Hamlyn, Sarah Fidler, Wolfgang Stöhr, et al.
HIV Clinical Trials|February 6, 2010
Monotherapy with Lopinavir/Ritonavir as maintenance after HIV-1 viral suppression: results of a 96-week randomized, controlled, open-label, pilot trial (KalMo study)Estevão P Nunes, Marilia Santini de Oliveira, Monica Merçon, et al.
Plos One|August 4, 2011
Effectiveness of protease inhibitor monotherapy versus combination antiretroviral maintenance therapy: a meta-analysisSandra Mathis, Bettina Khanlari, Federico Pulido, et al.
AIDS (London, England)|November 5, 2008
Long-term immunologic response to antiretroviral therapy in low-income countries: a collaborative analysis of prospective studiesDenis Nash, Monica Katyal, Martin W G Brinkhof, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|April 27, 2007
Discordant responses to potent antiretroviral treatment in previously naive HIV-1-infected adults initiating treatment in resource-constrained countries: the antiretroviral therapy in low-income countries (ART-LINC) collaborationSuely H Tuboi, Martin W G Brinkhof, Matthias Egger, et al.
Current Medical Research and Opinion|July 22, 2004
Predictors of adherence and virologic outcome in HIV-infected patients treated with abacavir- or indinavir-based triple combination HAART also containing lamivudine/zidovudinePedro Cahn, Asda Vibhagool, Mauro Schechter, et al.
BMC Infectious Diseases|June 20, 2024
T cell-mediated Immune response and correlates of inflammation and their relationship with COVID-19 clinical severity: not an intuitive guessNathalia Mantovani Pena, Luiz Claudio Santana, James R Hunter, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|September 29, 2015
The Safety of Tenofovir-Emtricitabine for HIV Pre-Exposure Prophylaxis (PrEP) in Individuals With Active Hepatitis BMarc M Solomon, Mauro Schechter, Albert Y Liu, et al.
Current Medical Research and Opinion|July 22, 2004
Triple nucleoside treatment with abacavir plus the lamivudine/zidovudine combination tablet (COM) compared to indinavir/COM in antiretroviral therapy-naïve adults: results of a 48-week open-label, equivalence trial (CNA3014)Asda Vibhagool, Pedro Cahn, Mauro Schechter, et al.
BMC Infectious Diseases|May 24, 2023
Dolutegravir-associated resistance mutations after first-line treatment failure in BrazilRicardo Sobhie Diaz, James R Hunter, Michelle Camargo, et al.
Pageof 12

Showing results (41-50 of 118) with videos related to

Sort By:
Pageof 12
AIDS (London, England)|December 5, 2013
Interleukin-6 and D-dimer levels at seroconversion as predictors of HIV-1 disease progressionElizabeth Hamlyn, Sarah Fidler, Wolfgang Stöhr, et al.
HIV Clinical Trials|February 6, 2010
Monotherapy with Lopinavir/Ritonavir as maintenance after HIV-1 viral suppression: results of a 96-week randomized, controlled, open-label, pilot trial (KalMo study)Estevão P Nunes, Marilia Santini de Oliveira, Monica Merçon, et al.
Plos One|August 4, 2011
Effectiveness of protease inhibitor monotherapy versus combination antiretroviral maintenance therapy: a meta-analysisSandra Mathis, Bettina Khanlari, Federico Pulido, et al.
AIDS (London, England)|November 5, 2008
Long-term immunologic response to antiretroviral therapy in low-income countries: a collaborative analysis of prospective studiesDenis Nash, Monica Katyal, Martin W G Brinkhof, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|April 27, 2007
Discordant responses to potent antiretroviral treatment in previously naive HIV-1-infected adults initiating treatment in resource-constrained countries: the antiretroviral therapy in low-income countries (ART-LINC) collaborationSuely H Tuboi, Martin W G Brinkhof, Matthias Egger, et al.
Current Medical Research and Opinion|July 22, 2004
Predictors of adherence and virologic outcome in HIV-infected patients treated with abacavir- or indinavir-based triple combination HAART also containing lamivudine/zidovudinePedro Cahn, Asda Vibhagool, Mauro Schechter, et al.
BMC Infectious Diseases|June 20, 2024
T cell-mediated Immune response and correlates of inflammation and their relationship with COVID-19 clinical severity: not an intuitive guessNathalia Mantovani Pena, Luiz Claudio Santana, James R Hunter, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|September 29, 2015
The Safety of Tenofovir-Emtricitabine for HIV Pre-Exposure Prophylaxis (PrEP) in Individuals With Active Hepatitis BMarc M Solomon, Mauro Schechter, Albert Y Liu, et al.
Current Medical Research and Opinion|July 22, 2004
Triple nucleoside treatment with abacavir plus the lamivudine/zidovudine combination tablet (COM) compared to indinavir/COM in antiretroviral therapy-naïve adults: results of a 48-week open-label, equivalence trial (CNA3014)Asda Vibhagool, Pedro Cahn, Mauro Schechter, et al.
BMC Infectious Diseases|May 24, 2023
Dolutegravir-associated resistance mutations after first-line treatment failure in BrazilRicardo Sobhie Diaz, James R Hunter, Michelle Camargo, et al.
Pageof 12